Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Voyager Therapeutics has signed its second major capsid licensing deal with Novartis, a $1.5 billion biobucks agreement that gives Novartis access to TRACER…
Voyager Therapeutics has granted Novartis target-specific access to its TRACER AAV capsids for CNS gene therapy programs in a deal worth up to $1.5 billion…
Novartis exercised its options to license novel capsids from Voyager's TRACER platform for two undisclosed neurologic disease targets; Voyager receives a…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Voyager Therapeutics entered a license option agreement with Novartis providing target-specific access to Voyager's TRACER AAV capsids for three CNS targets plus options for two more. Voyager received $54M upfront, plus option exercise fees and milestones up to $1.7B and tiered royalties on net sales. In March 2023 Novartis exercised its options to license TRACER-derived capsids for two undisclosed neurologic targets, triggering a $25M option-exercise payment to Voyager, with up to $600M in development, regulatory and commercial milestones for those products plus mid- to high-single-digit tiered royalties.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Novartis AG / Voyager Therapeutics Inc. (this deal) | 2022 | $1.8B | — |
| Novartis AG / Advanced Accelerator Applications S.A. | 2017 | $3.9B | 98 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Novartis AG / Lek Pharmaceuticals d.d. | 2002 | $876M | 88 |
| Novartis AG / GlaxoSmithKline plc | 2014 | $16.0B | 81 |
| Novartis AG / PTC Therapeutics Inc. | 2024 | $2.9B | 80 |
| Novartis AG / Chinook Therapeutics Inc. | 2023 | $3.5B | 78 |
← Browse all deals · How we score deals
More: 2022 deals · Novartis AG deals · Neurology deals